

Luciano L. Dasatinib: efficacy, side effects and role of comorbidities. Eur J Oncol 2014; 19 (2): 77-83

The author noted some corrections that need to fully replace the data already published.

In particular:

- page 77: Summary

“The majority of side effects were of low grade and manageable with dose adjustments. The pleural effusion rate was 24% at 5-years”

Should be read as:

“The majority of side effects were of low grade and manageable with dose adjustments. The pleural effusion rate was **29%** at 5-years”

- page 79: line 1

“The cCCyR rate, primary endpoint of the trial [...] while overall survival rates were 91 and 90% for Dasatinib and Imatinib, respectively.”

Should be read as:

“The cCCyR rate, primary endpoint of the trial, was 77% with Dasatinib and 66% with Imatinib at 12 months; the cumulative MMR rate after 5-year follow-up was 76 and **64%** in Dasatinib and Imatinib respectively. The cumulative rates of MR4 and MR4.5 at 5-years were higher for Dasatinib vs Imatinib (65 vs 49% and 42 vs 33%, respectively). The transformation to AP/BP occurred in lower percentage of patients in Dasatinib arm vs Imatinib arm (4,6 vs 7,3 %, respectively). At 5-years, the progression free survival was **86%** in both arms, while overall survival rates were 91 and 90% for Dasatinib and Imatinib, respectively.”

- page 79: line 12

“Moreover, the percentage of patients achieving BCR/ABL [...] at 6mo (69 vs 49%) and BCR/ ABL transcript $\leq 0,1\%$ at 12 months (46 vs 30%).”

Should be read as:

“Moreover, the percentage of patients achieving BCR/ABL transcript $\leq 10\%$ at **4** years was significantly higher for dasatinib than Imatinib (84 vs 64%, $p = <.0001$), as well as BCR/ ABL transcript $\leq 1\%$ at 6mo (69 vs 49%) and BCR/ ABL transcript $\leq 0,1\%$ at 12 months (46 vs 30%). **(14)**”

Ref. 14. Cortes JE, Hochhaus A, Kim D-W, et al. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) receiving dasatinib or imatinib: efficacy based an early response. Blood 2013, abs 653.

- page 80: line 27

“In DASISION trial the incidence [...] treatment as results of PAH (15).”

Should be read as:

In the DASISION trial fourteen dasatinib-treated patients experienced pulmonary hypertension by 2D echocardiogram, with right heart catheterization (RHC) performed in 1; 6 discontinued therapy. No patients were diagnosed with World Health Organization Group 1 pulmonary arterial hypertension (confirmed by RHC) (15).